NCNicholas David Calvert

Nicholas David Calvert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nicholas David Calvert has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • NIR-II scattering gold superclusters for intravascular optical coherence tomography molecular imaging

    by Nicholas D. Calvert, Joshua Baxter, Aidan A. Torrens, Jesse Thompson, Alexia Kirby, Jaspreet Walia, Spyridon Ntais, Eva Hemmer, Pierre Berini, Benjamin Hibbert, et al.

    Currently, intravascular optical coherence tomography (IV-OCT) is limited to anatomical imaging, providing structural information about atherosclerotic plaque morphology, thrombus and dissection. Earlier detection and risk stratification would be possible through molecular characterization of endothelium but necessitates a purpose-engineered IV-OCT contrast agent. Here we developed gold superclusters (AuSCs) tailored to clinical instrumentation and integrated into clinically relevant workflows. AuSCs are aqueously dispersible clusters of closely packed small gold nanoparticles, affording plasmon hybridization to maximize light scattering at the IV-OCT laser line (~1,350 nm). A polymer coating fosters AuSC uniformity and provides a functionalizable handle, which we targeted to intravascular P-selectin, an early vascular endothelial marker of inflammation. In a rat model of intravascular inflammation, P-selectin-targeted AuSC facilitated IV-OCT molecular imaging, where the strength of the signal correlates with the severity of vascular inflammation.


  • Open Access

    The careful selection of zwitterionic nanoparticle coating results in rapid and efficient cell labeling for imaging‐based cell tracking

    by Nicholas D. Calvert, Luciana Yu, Olivia C. Sehl, Julia J. Gevaert, Natasha N. Knier, Angelie Rivera‐Rodriguez, Clara S. Goulet, Nitara Fernando, Samantha Flood, Carlos M. Rinaldi‐Ramos, et al.

    The increased clinical application of cell‐based therapies has resulted in a parallel increase in the need for non‐invasive imaging‐based approaches for cell tracking, often through labeling with nanoparticles. An ideal nanoparticle for such applications must be biologically compatible as well as readily internalized by cells to ensure adequate and stable cell loading. Surface coatings have been used to make nanoparticle trackers suitable for these purposes, but those currently employed tend to have cytotoxic effects. Zwitterionic ligands are known to be biocompatible and antifouling; however, head‐to‐head evaluation of specific zwitterionic ligands for cell loading has not yet been explored. Magnetic particle imaging (MPI) detects superparamagnetic iron oxide nanoparticles (SPIONs) using time‐varying magnetic fields. Because MPI can produce high‐contrast, real‐time images with no tissue depth limitation, it is an ideal candidate for in vivo cell tracking. In this work, we have conjugated hard (permanently charged) and soft (pKa‐dependently charged) biomimetic zwitterionic ligands to SPIONs and characterized how these ligands changed SPION physicochemical properties. We have evaluated cellular uptake and subcellular localization between zwitterions, how the improvement in cell uptake generated stronger MPI signal for smaller numbers of cells, and how these cells can be tracked in an animal model with greater sensitivity for longer periods of time. Our best‐performing surface coating afforded high cell loading within 4 h, with full signal retention in vivo over 7 days.


  • Open Access

    pUdOs: Concise Plasmids for Bacterial and Mammalian Cells

    by France O. Manigat, Louise B. Connell, Brittany N. Stewart, Abdel-Rahman LePabic, Christian J. G. Tessier, Johnathon R. Emlaw, Nicholas D. Calvert, Anthony Rössl, Adam J. Shuhendler, Corrie J. B. Dacosta, et al.

    The plasmids from the Université d'Ottawa (pUdOs) are 28 small plasmids each comprising one of four origins of replication and one of seven selection markers, which together afford flexible use in Escherichia coli and several related gram-negative bacteria. The promoterless multicloning site is insulated from upstream spurious promoters by strong transcription terminators and contains type IIP or IIS restriction sites for conventional or Golden Gate cloning. pUdOs can be converted into efficient expression vectors through the insertion of a promoter at the user's discretion. For example, we demonstrate the utility of pUdOs as the backbone for an improved version of a Type III Secretion System reporter in Shigella. In addition, we derive a series of pUdO-based mammalian expression vectors, affording distinct levels of expression and transfection efficiency comparable to commonly used mammalian expression plasmids. Thus, pUdOs could advantageously replace traditional plasmids in a wide variety of cell types and applications.


  • Open Access

    Highly NIR-II Scattering Gold Superclusters for Intravascular Optical Coherence Tomography Molecular Imaging

    by Nicholas D. Calvert, Joshua Baxter, Aidan A. Torrens, Jesse Thompson, Alexia Kirby, Jaspreet Walia, Spyridon Ntais, Eva Hemmer, Pierre Berini, Benjamin Hibbert, et al.

    In North America, intravascular optical coherence tomography (IV-OCT) is performed every few minutes to evaluate atherosclerotic plaques and guide stent placement. Currently, IV-OCT is limited to anatomical imaging, providing structural information about atherosclerotic plaque morphology, thrombus, and dissection. Earlier detection and risk stratification would be possible through molecular characterization of endothelium but necessitates a purpose-engineered IV-OCT contrast agent. We developed gold superclusters (AuSC) tailored to clinical instrumentation and integrated into clinically relevant workflows. AuSC are aqueously dispersible clusters of closely packed small gold nanoparticles, affording plasmon hybridization to maximize light scattering at the IV-OCT laser line (~1350 nm). A polymer coating fosters AuSC uniformity and provides a functionalizable handle, which we targeted to intravascular P-selectin, an early vascular endothelial marker of inflammation. In a rat model of intravascular inflammation, P-selectin-targeted AuSC facilitated IV-OCT molecular imaging, where the strength of the signal correlates with the severity of vascular inflammation. AuSC thus enable in vivo molecular imaging, advancing IV-OCT into the molecular age.


  • Open Access

    Development of hydrogel‐based composite scaffolds containing eggshell particles for bone regeneration applications

    by Nicholas D. Calvert, Scott Proulx, Alejandro Rodriguez‐Navarro, Tamer Ahmed, Eric A. Lehoux, Maxwell T. Hincke, Isabelle Catelas

    This study describes the development and characterization of novel composite scaffolds, made of an alginate‐chitosan hydrogel matrix containing eggshell (ES) particles, for bone tissue engineering applications. Scaffolds with ES particles, either untreated or treated with phosphoric acid to create a nanotextured particle surface, were compared to scaffolds without particles. Results indicate that the nanotexturing process exposed occluded ES proteins orthologous to those in human bone extracellular matrix. Scaffolds with ES or nanotextured ES (NTES) particles had a higher porosity (81 ± 4% and 89 ± 5%, respectively) than scaffolds without particles (59 ± 5%) (p = .002 and p < .001, respectively). Scaffolds with NTES particles had a larger median pore size (113 μm [interquartile range [IQ]: 88–140 μm]) than scaffolds with ES particles (94 μm [IQ: 75–112 μm]) and scaffolds without particles (99 μm [IQ: 74–135 μm]) (p < .001 and p = .011, respectively). The compressive modulus of the scaffolds with ES or NTES particles remained low (3.69 ± 0.70 and 3.14 ± 0.62 kPa, respectively), but these scaffolds were more resistant to deformation following maximum compression than those without particles. Finally, scaffolds with ES or NTES particles allowed better retention of human mesenchymal stem cells during seeding (53 ± 12% and 57 ± 8%, respectively, vs. 17 ± 5% for scaffolds without particles; p < .001 in both cases), as well as higher cell viability up to 21 days of culture (67 ± 17% and 61 ± 11%, respectively, vs. 15 ± 7% for scaffolds without particles; p < .001 in both cases). In addition, alkaline phosphatase (ALP) activity increased up to 558 ± 164% on day 21 in the scaffolds with ES particles, and up to 567 ± 217% on day 14 in the scaffolds with NTES particles (p = .006 and p = .002, respectively, relative to day 0). Overall, this study shows that the physicochemical properties of the alginate‐chitosan hydrogel scaffolds with ES or NTES particles are similar to those of cancellous bone. In addition, scaffolds with particles supported early osteogenic differentiation and therefore represent a promising new bone substitute, especially for non‐load bearing applications.


  • Open Access

    Cell-Impermeable Inhibitors Confirm That Intracellular Human Transglutaminase 2 Is Responsible for the Transglutaminase-Associated Cancer Phenotype

    by Eric W. J. Gates, Nicholas D. Calvert, Nicholas J. Cundy, Federica Brugnoli, Pauline Navals, Alexia Kirby, Nicoletta Bianchi, Gautam Adhikary, Adam J. Shuhendler, Richard L. Eckert, et al.

    Transglutaminase 2 (TG2) is a multifunctional enzyme primarily responsible for crosslinking proteins. Ubiquitously expressed in humans, TG2 can act either as a transamidase by crosslinking two substrates through formation of an Nε(ɣ-glutaminyl)lysine bond or as an intracellular G-protein. These discrete roles are tightly regulated by both allosteric and environmental stimuli and are associated with dramatic changes in the conformation of the enzyme. The pleiotropic nature of TG2 and multi-faceted activities have resulted in TG2 being implicated in numerous disease pathologies including celiac disease, fibrosis, and cancer. Targeted TG2 therapies have not been selective for subcellular localization, such that currently no tools exist to selectively target extracellular over intracellular TG2. Herein, we have designed novel TG2-selective inhibitors that are not only highly potent and irreversible, but also cell impermeable, targeting only extracellular TG2. We have also further derivatized the scaffold to develop probes that are intrinsically fluorescent or bear an alkyne handle, which target both intra- and extracellular TG2, in order to facilitate cellular labelling and pull-down assays. The fluorescent probes were internalized and imaged in cellulo, and provide the first implicit experimental evidence that by comparison with their cell-impermeable analogues, it is specifically intracellular TG2, and presumably its G-protein activity, that contributes to transglutaminase-associated cancer progression.


  • Open Access

    pUdOs: concise plasmids for bacterial and mammalian cells

    by France Ourida Manigat, Louise B. Connell, Brittany N. Stewart, Abdel-Rahman LePabic, Christian J.G. Tessier, Johnathon R. Emlaw, Nicholas D. Calvert, Anthony Rössl, Adam J. Shuhendler, Corrie J.B. Dacosta, et al.

    The pUdOs are 28 plasmids of small size combining four different origins of replication and seven selection markers, which together afford flexible use in Escherichia coli and several related gram- negative bacteria. The promoterless multicloning site is insulated from upstream spurious promoters by strong transcription terminators, and contains type IIP or IIS restriction sites for conventional or Golden-gate cloning. pUdOs can be converted into efficient expression vectors through the insertion of a promoter at the user’s discretion. For example, we demonstrate the utility of pUdOs as the backbone for an improved version of a Type III Secretion System reporter in Shigella . In addition, we derive a series of pUdO-based mammalian expression vectors affording distinct levels of expression and transfection efficiencies comparable to commonly used mammalian expression plasmids. Thus, pUdOs could advantageously replace traditional plasmids in a wide variety of cell types and applications.


  • Open Access

    Direct mapping of kidney function by DCE-MRI urography using a tetrazinanone organic radical contrast agent

    by Nicholas D. Calvert, Alexia Kirby, Mojmír Suchý, Peter Pallister, Aidan A. Torrens, Dylan Burger, Gerd Melkus, Nicola Schieda, Adam J. Shuhendler

    Chronic kidney disease (CKD) and acute kidney injury (AKI) are ongoing global health burdens. Glomerular filtration rate (GFR) is the gold standard measure of kidney function, with clinical estimates providing a global assessment of kidney health without spatial information of kidney- or region-specific dysfunction. The addition of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) to the anatomical imaging already performed would yield a ‘one-stop-shop’ for renal assessment in cases of suspected AKI and CKD. Towards urography by DCE-MRI, we evaluated a class of nitrogen-centered organic radicals known as verdazyls, which are extremely stable even in highly reducing environments. A glucose-modified verdazyl, glucoverdazyl, provided contrast limited to kidney and bladder, affording functional kidney evaluation in mouse models of unilateral ureteral obstruction (UUO) and folic acid-induced nephropathy (FAN). Imaging outcomes correlated with histology and hematology assessing kidney dysfunction, and glucoverdazyl clearance rates were found to be a reliable surrogate measure of GFR.


  • Mapping vitamin B6 metabolism by hydrazoCEST magnetic resonance imaging

    by Emilie Marie Sophie Patit-Tha Brun, Nicholas David Calvert, Mojmír Suchý, Alexia Kirby, Gerd Melkus, Ruslan Garipov, Christina L. Addison, Adam J. Shuhendler

    2-Hydrazinonicotinic acid can selectively map the critical coenzyme pyridoxal 5′-phosphate by CEST-MRI in vitro and in vivo.